Pharmacological interventions for acute hepatitis B infection: An attempted network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2017, Pages

  Mantzoukis, Konstantinos ^a   Rodríguez Perálvarez, Manuel ^b   Buzzetti, Elena ^c   Thorburn, Douglas ^c   Davidson, Brian R ^a   Tsochatzis, Emmanuel ^c   Gurusamy, Kurinchi Selvan ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B ANTIBODY; INTERFERON; LAMIVUDINE; PLACEBO; ANTIVIRUS AGENT; GUANINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACUTE HEPATITIS B; CHRONIC HEPATITIS B; CLINICAL ASSESSMENT; CLINICAL OUTCOME; CONFIDENCE INTERVAL; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; EMBASE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDLINE; META ANALYSIS; MORTALITY; NETWORK META-ANALYSIS; ODDS RATIO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SCISEARCH; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; ANALOGS AND DERIVATIVES; CHRONIC HEPATITIS C; DISEASE COURSE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; PASSIVE IMMUNIZATION; PROCEDURES;

ACUTE DISEASE; ANTIVIRAL AGENTS; DISEASE PROGRESSION; GUANINE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C, CHRONIC; HUMANS; IMMUNIZATION, PASSIVE; INTERFERONS; LAMIVUDINE; NETWORK META-ANALYSIS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 85015748079     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011645.pub2     Document Type: Review

References (97)

1. Anonymous . Treatment of fulminant type B hepatitis with hepatitis B immune globulin a cooperative trial. Gastroenterology 1974;66:752. 5321568
2. Apostolescu CG, Rebeda I, Coltan G, Iacob SA, Caruntu FA. The efficacy of lamivudine in acute viral hepatitis with hepatitis B virus [abstract]. Journal of Hepatology 2001;34(1):144. 5321570
3. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology (Baltimore, Md.) 2007;45(1):97-101. 5321572
4. Streinu-Cercel A, Sandulescu O, Stefan M, Streinu-Cercel A. Treatment with lamivudine and entecavir in severe acute hepatitis B. Indian Journal of Medical Microbiology 2016;34(2):166-72. 5321574
5. Tassopoulos N, Hadziyannis S, Wright G. A randomized double-blind placebo-controlled trial of alpha-interferon in acute type II hepatitis. Hepatology (Baltimore, Md.) 1989;10(4):576. 5321576
6. Tassopoulos NC, Koutelou MG, Polychronaki H, Paraloglou-Ioannides M, Hadziyannis SJ. Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. Journal of Viral Hepatitis 1997;4(6):387-94. 5321578
7. Wiegand J, Wedemeyer H, Franke A, Roessler S, Zeuzem S, Teuber G, et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. Journal of Viral Hepatitis 2014;21(10):744-50. 5321580
8. Wiegand J, Wedemeyer H, Franke A, Stolzel U, Zeuzem S, Teuber G, et al. Treatment of acute hepatitis B with lamivudine vs. placebo: a prospective randomized multicenter trial. Hepatology (Baltimore, Md.) 2012;56:385A-6A. 5321581
9. Blum AL, Berthet P, Doelle W, Goebell H, Kortum K, Pelloni S, et al. Treatment of acute viral hepatitis with (+)-cyanidanol-3. Lancet 1977;2(8049):1153-5. 5321583
10. Botero RC, Delgado C. Placebo controlled trial of intravenous s-adenosylmetionine (SAME) in patients with acute hepatitis-A, hepatitis-B, and NNB. Hepatology (Baltimore, Md.) 1991;14(4):A199-200. 5321585
11. Flisiak R, Prokopowicz D. One year follow-up of patients treated with misoprostol in acute phase of viral hepatitis B. Prostaglandins & Other Lipid Mediators 2000;60(4-6):161-5. 5321587
12. Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. New England Journal of Medicine 1976;294(13):681-7. 5321589
13. Sharapov M. Treatment with alfa-2 interferon in children with acute hepatitis B. Gut 2000;47(Suppl III):A287. 5321591
14. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. Journal of Viral Hepatitis 2006;13(4):256-63. 5321593
15. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Digestive Diseases & Sciences 2010;55(3):775-83. 5321595
16. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: update 2009. www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf (accessed 13 October 2014).
17. Anonymous . Interferon production by genetic engineering. British Medical Journal (Clinical Research Ed.) 1981;282(6265):674-5.
18. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chemistry 2001;12(2):195-202.
19. Bass S, Zook N. Intravenous acetylcysteine for indications other than acetaminophen overdose. American Journal of Health-System Pharmacy 2013;70(17):1496-501.
20. Bruno R, Carosi G, Coppola N, Gaeta GB, Puoti M, Santantonio T, et al. Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT). Infection 2014;42(5):811-5.
21. Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis - United States, 2014. www.cdc.gov/hepatitis/statistics/2014surveillance/pdfs/2014hepsurveillancerpt.pdf (accessed on 12 February 2017).
22. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 2012;3(2):161-76.
23. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8(10):e76654.
24. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7.
25. Choi HJ, Ko SY, Choe WH, Seo YS, Kim JH, Byun KS, et al. Clinical features of acute viral hepatitis B in Korea: a multi-center study. Korean Journal of Hepatology 2011;17(4):307-12.
26. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Seminars in Liver Disease 2006;26(2):142-52.
27. Coppola N, Sagnelli C, Pisaturo M, Minichini C, Messina V, Alessio L, et al. Clinical and virological characteristics associated with severe acute hepatitis B. Clinical Microbiology and Infection 2014;20(12):O991-7.
28. Del Re AC, Spielmans GI, Flückiger C, Wampold BE. Efficacy of new generation antidepressants: differences seem illusory. PLoS One 2013;8(6):e63509.
29. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
30. Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virology Journal 2012;9:185.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
32. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29(7-8):932-44.
33. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical Support Document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012). www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20report.08.05.12.pdf (accessed 27 March 2014).
34. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: introduction to evidence synthesis for decision making, April 2011 (last updated April 2012). www.nicedsu.org.uk/TSD1%20Introduction.final.08.05.12.pdf (accessed 27 March 2014).
35. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pair wise and network meta-analysis of randomised controlled trials, August 2011 (last updated April 2014). www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf (accessed 8 October 2014).
36. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014). www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf (accessed 8 October 2014).
37. European Association for Study of Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology 2012;57(1):167-85.
38. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
39. EuroQol . About EQ-5D. www.euroqol.org/about-eq-5d.html (accessed 8 October 2014).
40. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436(7053):967-72.
41. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. New England Journal of Medicine 2004;350(11):1118-29.
42. Garfein RS, Bower WA, Loney CM, Hutin YJ, Xia GL, Jawanda J, et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology (Baltimore, Md.) 2004;40(4):865-73.
43. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2016, Issue 10. Art. No.: LIVER.
44. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
45. Higgins JPT, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
46. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods 2012;3(2):98-110.
47. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of hepatitis B: summary of a clinical research workshop. Hepatology (Baltimore, Md.) 2007;45(4):1056-75.
48. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania: Barnett International/PAREXEL, 1997.
49. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014;14(1):120.
50. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
51. Kumar M, Jain S, Sharma BC, Sarin SK. Differentiating acute hepatitis B from the first episode of symptomatic exacerbation of chronic hepatitis B. Digestive Diseases and Sciences 2006;51(3):594-9.
52. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. Journal of Hepatology 2001;35(1):134-46.
53. Leen CL, Davison SM, Flegg PJ, Mandal BK. Seven years experience of acute hepatitis B in a regional department of infectious diseases and tropical medicine. Journal of Infection 1989;18(3):257-63.
54. Li J, Liu CH, Wang FS. Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides 2010;31(11):2151-8.
55. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. Journal of Gastroenterology and Hepatology 2011;26(Suppl 1):123-30.
56. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101(474):447-59.
57. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3]
58. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
59. Sweetman S, editor . Martindale: the complete drug reference (online version), 37th edition, 2011. www.pharmpress.com/product/MC_MART/martindale-the-complete-drug-reference (accessed 23 September 2014).
60. McMahon BJ. Chronic hepatitis B virus infection. Medical Clinics of North America 2014;98(1):39-54.
61. Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308(12):1246-53.
62. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
63. NCBI . Interferons, 2014. www.ncbi.nlm.nih.gov/mesh/68007372 (accessed 11 October 2014).
64. NCBI . Thymosins, 2014. www.ncbi.nlm.nih.gov/mesh/68013947 (accessed 15 October 2014).
65. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378(9791):571-83.
66. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
67. Members of OpenBUGS Project Management Group. OpenBUGS. Version 3.2.3. Members of OpenBUGS Project Management Group, 2014.
68. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ (Clinical Research Ed.) 2014;349:g5630.
69. The Nordic Cochrane Centre, Cochrane. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, Cochrane, 2014.
70. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
71. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71.
72. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):80-97.
73. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82.
74. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
75. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
76. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical Research Ed.) 2010;340:c332.
77. Severini TA. Bayesian interval estimates which are also confidence intervals. Journal of the Royal Statistical Society. Series B (Methodological) 1993;55(2):533-40.
78. Sharif O, Krishnan PV, Thekdi AD, Gordon SC. Acute hepatitis B in an urban tertiary care hospital in the United States: a cohort evaluation. Journal of Clinical Gastroenterology 2013;47(9):e87-90.
79. Shi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis. International Journal of Infectious Diseases 2010;14(7):e622-34.
80. Souza LA, Mattos AA, Fiorini M, Ribeiro P, Tovo CV. Clinical outcome of a patient cohort with acute hepatitis B. Clinics 2013;68(5):718-20.
81. StataCorp LP. Stata/SE 14.2 for Windows[64-bit x86-64]. Version 14. College Station: StataCorp LP, 2017.
82. Tanwar S, Dusheiko G. Is there any value to hepatitis B virus genotype analysis?. Current Gastroenterology Reports 2012;14(1):37-46.
83. Thiele M, Gluud LL, Fialla AD, Dahl EK, Krag A. Large variations in risk of hepatocellular carcinoma and mortality in treatment naive hepatitis B patients: systematic review with meta-analyses. PLoS One 2014;9(9):e107177.
84. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Annals of Internal Medicine 2009;150(1):33-9.
85. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 24 November 2016).
86. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Systematic Reviews 2012;1:41.
87. Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?. Liver International 2012;32(4):544-53.
88. Tillmann HL, Patel K. Therapy of acute and fulminant hepatitis B. Intervirology 2014;57(3-4):181-8.
89. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
90. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818-27.
91. van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Research Synthesis Methods 2012;3(4):285-99.
92. Ware JE. SF-36® health survey update, 2014. www.sf-36.org/tools/sf36.shtml (accessed on 8 October 2014).
93. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
94. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology 2017;17(1):39.
95. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5.
96. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993;342(8883):1340-4.
97. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. Journal of Viral Hepatitis 2009;16(4):265-71.